Zenagamtide and the AMAZE 9 trial
Zenagamtide is the investigational peptide previously called amycretin. It is a single molecule with activity at GLP-1, amylin and calcitonin receptors. Novo's November 4 update highlights AMAZE 9, an oral Phase 3 obesity trial; it should not be confused with the molecule's earlier oral diabetes trial or its injectable program. 1 2
Are zenagamtide and amycretin different peptides?
The published oral Phase 2 paper identifies zenagamtide as formerly amycretin. The name change can make two descriptions of the same development molecule look like different drugs. The dosage form and trial identifier are therefore more useful than the name alone when comparing reports. 1
A single molecule acting through several receptors is also different from combining two separately named compounds. Similar pathway descriptions do not establish the same formulation, clinical effects or development status.
What is AMAZE 9 designed to measure?
ClinicalTrials.gov identifies AMAZE 9 as NCT07720271. It is a randomized, masked Phase 3 comparison of oral zenagamtide and matched placebo, with planned enrollment of 950. The primary outcome is relative body-weight change at week 76. 3
| Detail | AMAZE 9 registry |
|---|---|
| Intervention | Oral zenagamtide tablets |
| Comparator | Matched placebo |
| Primary outcome | Relative body-weight change at 76 weeks |
| Enrollment | 950 planned participants |
| Recorded status | Recruiting in the September 28 update checked November 5 |
How does that differ from the earlier oral trial?
The published Phase 2 oral study enrolled adults with type 2 diabetes and assessed HbA1c change at 36 weeks. Its abstract reports improved HbA1c at the evaluated dose levels and describes gastrointestinal adverse events. That is a different primary question and follow-up period from AMAZE 9. 1
An earlier positive result can justify further study without predicting the later trial's outcome. In particular, a diabetes endpoint should not silently become an obesity endpoint, and an injectable result should not be relabeled as an oral result.
When are results expected?
Novo's latest report places the expected AMAZE 9 readout in the second half of 2028. That is a sponsor forecast, not a guaranteed publication date or an approval timetable. 2
The registry's estimated primary-completion date and a company's anticipated readout can differ because collecting the main outcome, analyzing the data and announcing results are separate events. The current record should be consulted whenever a timeline is updated. 3
Is zenagamtide an approved oral medicine?
The sources used here describe an investigational development program. They do not announce approval or commercial availability. Oral semaglutide products have separate identities and labels; the existence of those products does not establish a regulatory pathway has finished for zenagamtide. 1 2
The most useful future update will identify the exact oral trial, its prespecified outcomes and any new regulatory decision. That keeps the aliases, dosage forms and evidence stages connected without treating them as interchangeable.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.